2. Others NF-κB Immunology/Inflammation Apoptosis Cell Cycle/DNA Damage PI3K/Akt/mTOR MAPK/ERK Pathway Stem Cell/Wnt
  3. Drug Isomer NF-κB NO Synthase TNF Receptor Interleukin Related IFNAR COX CD20 CDK Bcl-2 Family Apoptosis Akt p38 MAPK GSK-3
  4. (-)-Syringaresinol

(-)-Syringaresinol  (Synonyms: (-)-丁香树脂酚)

目录号: HY-126066 纯度: 99.95%
COA 产品使用指南 技术支持

(-)-Syringaresinol 是一种可在 Annona Montana 中发现的具有口服活性的 Syringaresinol (HY-N8307) 异构体。(-)-Syringaresinol 具有抗氧化、抗炎和抗癌等活性。(-)-Syringaresinol 通过 PI3K-Akt/MAPK/Wnt 信号通路可以减轻溃疡性结肠炎。(-)-Syringaresinol 通过阻滞 G1 期并诱导细胞凋亡 (apoptosis) 来抑制 HL-60 细胞的增殖。(-)-Syringaresinol 通过下调 NF-kB p65 信号通路及其与 ERβ 的相互作用抑制 LPS (HY-D1056) 诱导的小胶质细胞激活，发挥抗神经炎症作用。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

(-)-Syringaresinol

(-)-Syringaresinol Chemical Structure

CAS No. : 6216-81-5

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
1 mg ￥580
In-stock
5 mg ￥1450
In-stock
10 mg ￥2350
In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of (-)-Syringaresinol:

(-)-Syringaresinol 相关抗体

Top Publications Citing Use of Products

查看 NF-κB 亚型特异性产品:

查看所有亚型
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

查看 NO Synthase 亚型特异性产品:

查看所有亚型
nNOS iNOS eNOS

查看 TNF Receptor 亚型特异性产品:

查看所有亚型
TNFRSF1A/CD120a TNFRSF3/CD18 TNFRSF4 TNFRSF5/CD40 TNFRSF6/Fas/CD95 TNFRSF7/CD27 TNFRSF8/CD30 TNFRSF9/4-1BB/CD137 TNFRSF12A/TWEAK TNFRSF16/NGF Receptor/CD271 TNFRSF18/GITR/CD357

查看 Interleukin Related 亚型特异性产品:

查看所有亚型
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22

查看 COX 亚型特异性产品:

查看所有亚型
COX COX-1 COX-2 COX-3

查看 CDK 亚型特异性产品:

查看所有亚型
CDK1 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CDK11 CDK12 CDK13 CDK14 CDK16 CDK19 CDC CLK Pho85 CDK10 CDK15 CDK17 CDK18 CDK20 PITSLRE

查看 Bcl-2 Family 亚型特异性产品:

查看所有亚型
Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim BNIP3

查看 Akt 亚型特异性产品:

查看所有亚型
Akt Akt1 Akt2 Akt3

查看 p38 MAPK 亚型特异性产品:

查看所有亚型
p38 MAPK p38α p38β MAPK13 p38δ p38γ

查看 GSK-3 亚型特异性产品:

查看所有亚型
GSK-3 GSK-3α GSK-3β

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

(-)-Syringaresinol is an orally active isomer of syringaresinol (HY-N8307) found in Annona Montana. (-)-Syringaresinol exhibits antioxidant, anti-inflammatory, and anticancer activities. (-)-Syringaresinol can alleviate ulcerative colitis via the PI3K-Akt/MAPK/Wnt signaling pathway. (-)-Syringaresinol inhibits HL-60 cell proliferation by arresting the G1 phase and inducing apoptosis. (-)-Syringaresinol inhibits LPS (HY-D1056)-induced microglial activation by downregulating the NF-κB p65 signaling pathway and its interaction with ERβ, exerting anti-neuroinflammatory effects[1][2][3].

细胞效力
(Cellular Effect)
Cell Line Type Value Description References
A549 IC50
> 30 μM
Compound: 7
Anticancer activity against human A549 cells by SRB assay
Anticancer activity against human A549 cells by SRB assay
[PMID: 21420296]
BV-2 IC50
> 100 μM
Compound: 17
Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay
Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay
[PMID: 28911817]
BV-2 IC50
27.53 μM
Compound: 5; Syringaresinol
Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
[PMID: 26774654]
RAW264.7 IC50
> 50 μM
Compound: 9
Inhibition of LPS-induced IL-1beta production in mouse RAW264.7 cells after 24 hrs by ELISA
Inhibition of LPS-induced IL-1beta production in mouse RAW264.7 cells after 24 hrs by ELISA
[PMID: 24963714]
RAW264.7 IC50
45.6 μM
Compound: 9
Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs by Griess reagent based assay
Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs by Griess reagent based assay
[PMID: 24963714]
SK-MEL-2 IC50
14.47 μM
Compound: 7
Anticancer activity against human SK-MEL-2 cells by SRB assay
Anticancer activity against human SK-MEL-2 cells by SRB assay
[PMID: 21420296]
SK-OV-3 IC50
> 30 μM
Compound: 7
Anticancer activity against human SKOV3 cells by SRB assay
Anticancer activity against human SKOV3 cells by SRB assay
[PMID: 21420296]
XF498 IC50
8.82 μM
Compound: 7
Anticancer activity against human XF498 cells by SRB assay
Anticancer activity against human XF498 cells by SRB assay
[PMID: 21420296]
体外研究
(In Vitro)

(-)-Syringaresinol (25-100 μM,，24 小时) 在 LPS (HY-D1056) 诱导的 Caco-2 细胞中可增强肠上皮屏障功能，降低 TNF-α、IL-6、IFN-γ 和 COX-2 的水平，并增加紧密连接蛋白表达水平[1]。
(-)-Syringaresinol (0.5-40 μM,，24-72 小时) 可降低 HL-60 细胞的细胞活力 (IC50 = 5.8 μM,)，对 SNU-1、SK-OV-3、LLC 细胞具有弱细胞毒性 (IC50 > 30 μM)[2]。
(-)-Syringaresinol (0-20 μM,，0-24 小时) 可诱导 HL-60 细胞凋亡、G1 期阻滞和细胞色素 c 的释放[2]。
(-)-Syringaresinol (0-200 μM,, 24 小时) 对 BV2 细胞无毒性作用[3]。
(-)-Syringaresinol (25-100 μM,, 1 小时) 可抑制 LPS 诱导的促炎介质产生，并上调 BV2 细胞中 NO 的产生[3]。
(-)-Syringaresinol (25-100 μM,, 24 小时) 可增加 LPS 刺激的 BV2 细胞中 M2 标志物 CD206 的表达，但抑制 M1 标志物 CD40 的表达[3]。
(-)-Syringaresinol (50 μM,, 1 小时) 可通过 ERβ 在 LPS 刺激的 BV2 细胞中发挥抗炎作用[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

(-)-Syringaresinol 相关抗体:

Immunofluorescence[1]

Cell Line: LPS-induced Caco-2 cell
Concentration: 25 μM, 50 μM, 100 μM
Incubation Time: 24 h
Result: Increased expression levels of ZO-1, occludin, claudin-1, and E-cadherin.

Cell Cycle Analysis[2]

Cell Line: HL-60 cells
Concentration: 1 μM
Incubation Time: 0 h, 4 h, 8 h, 16 h, 24 h
Result: Arrested in G1, did not change S phase, increased the expressions of p21waf1/cip1 and p27kip1, decreased the expressions of cyclin D1, cyclin D2, and cyclin E as well as cdk2, cdk4 and cdk6.

Apoptosis Analysis[2]

Cell Line: HL-60 cells
Concentration: 0 μM, 0.5 μM, 5 μM, 20 μM
Incubation Time: 24 h
Result: Showed nuclear fragmentation and cell shrinkage, increased the expression of Bax and the ratio of Bax/Bcl-2, decreased the expressions of Bcl-2 and Bcl-XL.

Western Blot Analysis[2]

Cell Line: HL-60 cells
Concentration: 0 μM, 0.5 μM, 5 μM, 20 μM
Incubation Time: 24 h
Result: Increased cleavage of caspase-9, caspase-3, and PARP.

RT-PCR[3]

Cell Line: BV2 cells
Concentration: 25 μM, 50 μM, 100 μM
Incubation Time: 1 h
Result: Attenuated the LPS-induced transcription levels of proinflammatory mediator IL-6, IL-1β, TNF-α, iNOS, and COX-2.

ELISA Assay[3]

Cell Line: BV2 cells
Concentration: 25 μM, 50 μM, 100 μM
Incubation Time: 1 h
Result: Downregulated LPS-induced TNF-α and IL-6 levels.

Western Blot Analysis[3]

Cell Line: BV2 cells
Concentration: 25 μM, 50 μM, 100 μM
Incubation Time: 1 h
Result: Attenuated the LPS-induced COX-2 and iNOS protein expression.
Reduced the LPS-induced activation of NF-κB p65.
体内研究
(In Vivo)

(-)-Syringaresinol (10-40 mg/kg，灌胃，每日一次， 10 天) 在 Dextran sodium sulfate (DSS) (HY-116282C) 诱导的溃疡性结肠炎 (UC) 小鼠模型通过参与调控 PI3K-Akt/MAPK/Wnt 信号通路，减轻炎症反应，降低肠道上皮通透性[1]。
(-)-Syringaresinol (60 mg/kg，灌胃，每日一次，2 天) 可减轻 LPS 刺激小鼠模型中海马区和胼胝体中的炎症反应，并抑制星形胶质细胞活化[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: DSS-induced UC mouse model [1]
Dosage: 10 mg/kg, 20 mg/kg, 40 mg/kg,
Administration: i.g., once a day, 10 days
Result: Reduced weight loss and DAI scores, increased colon length and reduced colon damage, reduced spleen coefficient.
Reduced bacterial levels in the spleen and mesenteric lymph nodes, reduced serum TNF-α, IL-6, IFN-γ and COX-2 levels.
Showed lower epithelial damage, more intact colon tissue and lower inflammatory cell infiltration than the contorl group.
Improved colonic epithelial cell ultrastructure and gradually restored tight and gap junction integrity.
Reduced mRNA expression of Pdgfra, Tgfbr2, Il1r1, Cacna1d, Fn1, Lamc1, Col4a1, Col1a1, Srfp1, Wnt4, Fzd1, and Wnt5b, reduced phosphorylation levels of PI3K, Akt, NF-κB, MAPK, and GSK-3β, as well as β-catenin, increased expression of E-cadherin.
Animal Model: LPS (100 mg/kg)-stimulated C57BL/6 mice (Male 8-12-week-old) model[3]
Dosage: 60 mg/kg
Administration: i.g., once a day, 2 days
Result: Reduced the mRNA levels of IL-6, IL-1β, TNF-α, COX-2, and iNOS in the mouse hippocampal region.
Suppressed LPS-induced astrocytes activation in the hippocampal area and corpus callosum.
分子量

418.44

Formula

C22H26O8
CAS 号
性状

固体

颜色

White to off-white

中文名称

(-)-丁香树脂酚
结构分类
初始来源
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据
细胞实验： 

DMSO 中的溶解度 : 100 mg/mL (238.98 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.3898 mL 11.9491 mL 23.8983 mL
5 mM 0.4780 mL 2.3898 mL 4.7797 mL
查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量
=
浓度
×
体积
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

C1

×
体积 (start)

V1

=
浓度 (final)

C2

×
体积 (final)

V2

动物实验：

请根据您的 实验动物和给药方式 选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 方案 一

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (5.97 mM); 澄清溶液

    此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水 定容至 1 mL。

    生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
  • 方案 二

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (5.97 mM); 澄清溶液

    此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中，混合均匀。

    2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
动物溶解方案计算器
请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

g

每只动物的给药体积

μL

动物数量

只
由于实验过程有损耗，建议您多配一只动物的量
请输入您的动物体内配方组成：
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
方案所需 助溶剂 包括：DMSO， ，均可在 MCE 网站选购。 ，Tween 80，均可在 MCE 网站选购。
计算结果
工作液所需浓度 : mg/mL
储备液配制方法 : mg 药物溶于 μL  DMSO（母液浓度为 mg/mL）。

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。
动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。
连续给药周期超过半月以上，请谨慎选择该方案。
请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热 （超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。
纯度 & 产品资料

纯度: 99.95%

COA (296 KB) HNMR (203 KB) CNMR (160 KB) RP-HPLC (327 KB) MS (601 KB)

产品使用指南 (1538 KB)
参考文献

(-)-Syringaresinol 相关分类

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.3898 mL 11.9491 mL 23.8983 mL 59.7457 mL
5 mM 0.4780 mL 2.3898 mL 4.7797 mL 11.9491 mL
10 mM 0.2390 mL 1.1949 mL 2.3898 mL 5.9746 mL
15 mM 0.1593 mL 0.7966 mL 1.5932 mL 3.9830 mL
20 mM 0.1195 mL 0.5975 mL 1.1949 mL 2.9873 mL
25 mM 0.0956 mL 0.4780 mL 0.9559 mL 2.3898 mL
30 mM 0.0797 mL 0.3983 mL 0.7966 mL 1.9915 mL
40 mM 0.0597 mL 0.2987 mL 0.5975 mL 1.4936 mL
50 mM 0.0478 mL 0.2390 mL 0.4780 mL 1.1949 mL
60 mM 0.0398 mL 0.1992 mL 0.3983 mL 0.9958 mL
80 mM 0.0299 mL 0.1494 mL 0.2987 mL 0.7468 mL
100 mM 0.0239 mL 0.1195 mL 0.2390 mL 0.5975 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

(-)-Syringaresinol6216-81-5(-)-丁香树脂酚Drug IsomerNF-κBNO SynthaseTNF ReceptorInterleukin RelatedIFNARCOXCD20CDKBcl-2 FamilyApoptosisAktp38 MAPKGSK-3Nuclear factor-κBNuclear factor-kappaBNitric oxide synthasesNOSTumor Necrosis Factor ReceptorTNFRILInterferon-α/β receptorInterferon-alpha/beta receptor CyclooxygenaseCyclin dependent kinasePKBProtein kinase BGlycogen synthase kinase-3Glycogen synthase kinase 3Antioxidantanti-inflammatoryanticancerHL-60 cellsapoptosisBV2 cellsDSSUC mouse modelInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
(-)-Syringaresinol
目录号：
HY-126066
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z